Patient Satisfaction And Disease Control In Patients With Systemic Lupus Erythematosus Is Not Affected By Switching From Intravenous Belimumab To Subcutaneous Injections

PURPOSE: Since the launch of belimumab in 2011, the BLyS antibody has been increasingly used in the therapy of systemic Lupus erythematosus (SLE). Comparative studies showed that the intravenous (i.v.) and subcutaneous (s.c.) administration forms do not differ in their efficacy. Since the approval o...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Patient Prefer Adherence
Main Authors: Mucke, Johanna, Brinks, Ralph, Fischer-Betz, Rebecca, Richter, Jutta G, Sander, Oliver, Schneider, Matthias, Chehab, Gamal
Format: Artigo
Jezik:Inglês
Izdano: Dove 2019
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6839583/
https://ncbi.nlm.nih.gov/pubmed/31806937
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PPA.S227208
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki